HARP - Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting | Benzinga
Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:
– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS –
Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to be presented by the end of 2023
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the presentation of interim data for the 2.15 to 12 mg target dose cohorts from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM). HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's immune cells to kill tumor cells. The data will be presented at the 20th International Myeloma Society (IMS) Annual Meeting in a poster presentation on September 28, 2023 in Athens, Greece.
As of the data cut-off on August 12, 2023, 97 patients were treated with HPN217 across 14 dose escalation cohorts. The trial enrolled heavily pre-treated patients, of whom 65% were penta-drug exposed and 20% had been treated with BCMA-targeted agents.
In patients at the 12 mg target dose (N=19), a manageable tolerability profile was observed with low rates of CRS (16%, all G1-2) and no ICANS. Additionally, robust, early clinical activity (63% ORR) was seen. Treatment remains ongoing in 7 responders, while the median responder time on treatment continues to mature, currently 8.3 months (6.0-17.3+).
For the earlier 2.15 mg to 6 mg target dose cohorts, the median ...